Easton Pharmaceuticals Inc.

June 21, 2011 06:00 ET

Easton Pharmaceuticals Announces Dr. Jack Barkin MD, World-Renowned Expert on Disorders of Sexual Dysfunction, Has Accepted The Position as Senior Vice-President, Chief Medical Officer

TORONTO, ONTARIO--(Marketwire - June 21, 2011) - Easton Pharmaceuticals (OTC:EAPH), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, announced today that Jack Barkin, MD, fics, facs, dabu, mhm, ccpe, frcs (c) has agreed to join the company as Senior Vice-President and Chief Medical Officer. Dr. Barkin is the past Chief Urologist and present Chief of Staff at a university affiliated Toronto hospital, and an Assistant Professor in the Department of Surgery at the University of Toronto.

Dr. Barkin is a Director of the Society of Urologic Surgeons of Ontario, Vice-President of The Canadian Society for the Study of the Aging Male, Vice- Chairman of The Canadian Male Sexual Health Council, a Fellow of the Royal College of Physicians and Surgeons of Canada, and a Fellow of the American College of Surgeons. He recently became one of the first "Canadian Certified Physician Executives". He is also the Executive Deputy Editor of the Canadian Journal of Urology for whom he has recently written and edited The Update in Urology for Primary Care Practitioners, including a large article on Erectile Dysfunction and Hypogonadism. Over the past 25 years, Dr Barkin has been a principal investigator in over 125 international clinical trials on various aspects of urology, has special interests in male and female sexual function disorders, and was the keynote speaker at the Canadian press conference launch for Viagra, Cialis, and Levitra.

"We are especially pleased to have such an accomplished professional as Dr. Barkin on board to help with our clinical plans for our products, beginning with our lead product VIORRA," says John Easton, Easton Pharmaceuticals' CEO & Chairman of the Board. "Dr. Barkin's vast experience in the sexual dysfunction market will help us navigate the sometimes uncertain waters of the market, and will help us focus on the design and execution of key clinical trials that will enrich our pending commercialization efforts."

Dr. Barkin is also a member of numerous medical advisory boards for leading pharmaceutical companies including Pfizer, Eli Lilly, Bayer, Merck, Abbott, Jansen-Ortho, Allergan, Ferring, Paladin, GSK, Sanofi, and Astra Zeneca. Dr. Barkin's credentials also include expert appearances on numerous notable TV shows, network programs, and speaking engagements throughout the world on all aspects of sexual function disorders. He has published extensively in numerous medical journals and is an expert reviewer for many urologic journals. He has participated in many Canadian press conferences, and helped launch many new pharmaceuticals for such companies as Jansen Ortho, Pfizer, Lilly, Solvay, Astra Zeneca and Bayer.

About Easton Pharmaceuticals Inc.

Toronto-based Easton Pharmaceuticals is a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, focused on skin and circulatory conditions that impact a large and expanding numbers of consumers including health issues related to male and female sexual dysfunction, scar and stretch marks, cellulite and varicose veins, the world market for these conditions is in excess of $10 billion.

The company's proprietary gel formulation is an innovative and unique transdermal delivery system. Easton Pharmaceuticals' flagship product, VIORRA, is an over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity which has a very positive effect on women's sexual desire and arousal, FSAD (Female Sexual Arousal Disorder) the world market for these female conditions are in excess of $2 billion. VIORRA is a topical, daily-use product classified by the FDA as containing Generally Recognized as Safe ingredients.

For more information, visit http://www.eastonpharma.com.

Safe Harbor

This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "pleased," "plan," "confident that," "believe," "expect," or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing and other risks as stated in the company's financial reports and filings.

Copyright ©2011 Easton Pharmaceuticals Inc. All rights reserved. Easton Pharmaceuticals, Easton Pharma and the Easton Pharmaceuticals logo, and all other Easton Pharmaceuticals company, product, and services names and slogans are trademarks or registered trademarks of Easton Pharmaceuticals Inc.

Contact Information